Ambirix confers immunity against hepatitis A and hepatitis B infection by inducing specific anti-hepatitis A and anti-hepatitis B antibodies.
The hepatitis A component of the vaccine consists of inactivated hepatitis A virus and the hepatitis B component is a surface antigen produced by recombinant DNA technology.
Ambirix is for use in non-immune patients aged 1—15 years, and unlike Twinrix (GSK’s other combined hepatitis A and B vaccine) which requires a threedose regimen, the standard primary vaccination course consists of two doses.
The first dose should be given on an elected date and the second dose given between six and 12 months later. The vaccine should be administered in a setting where completion of the two-dose course can be assured.
Protection against hepatitis B infections may not be obtained until after the second dose; Ambirix should only be used when there is a low risk of hepatitis B infection during the vaccination course.
Further information: GlaxoSmithKline